Payment overview · 2025
General Payments
$63,710.01
128 reported records · 13 companies
Healthcare provider profile · identity verified
James Matthew Andry, MD
Allopathic & Osteopathic Physicians|Family Medicine · BLOOMINGTON, IN · NPI 1447255369
Verified facts
What the public records show
CMS Open Payments records show James Matthew Andry, MD received $63,710.01 in general payments during 2025 across 128 reported records.
Lilly USA, LLC accounted for 80.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51,293.27 | 80.5% | 75 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $9,964.47 | 15.6% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $1,877.44 | 3.0% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $205.06 | 0.3% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $111.02 | 0.2% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $86.52 | 0.1% | 5 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $39.29 | 0.1% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.42 | 0.0% | 3 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.26 | 0.0% | 1 | 2025 |
| Ultragenyx Pharmaceutical Inc. | Unresolved — no canonical attribution shown | $22.95 | 0.0% | 1 | 2025 |
| Avvisto Therapeutics, LLC | Unresolved — no canonical attribution shown | $20.69 | 0.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.90 | 0.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.72 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $51,177.44 | 40 |
| Travel and Lodging | $10,529.30 | 20 |
| Food and Beverage | $2,003.27 | 68 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $45,960.38 | 67 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $9,964.47 | 18 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $5,089.82 | 12 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $1,877.44 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $205.06 | 13 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $126.01 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $86.25 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $86.25 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $68.14 | 4 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $39.29 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $28.42 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| Dojolvi Normalized: dojolvi |
Drug | Ultragenyx Pharmaceutical Inc. | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| CYCLOSET Normalized: cycloset |
Drug | Avvisto Therapeutics, LLC | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 155 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
155 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Mounjaro | Tirzepatide | 155 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 133 | 32 |
| Metformin Hcl Er | Metformin Hcl | 104 | 29 |
| Alprazolam | Alprazolam | 100 | 22 |
| Atorvastatin Calcium | Atorvastatin Calcium | 96 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 92 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 74 | 15 |
| Tramadol Hcl | Tramadol Hcl | 74 | 12 |
| Progesterone | Progesterone, Micronized | 73 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 63 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 61 | 18 |
| Lisinopril | Lisinopril | 58 | 14 |
| Amlodipine Besylate | Amlodipine Besylate | 54 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | suppressed |
| Azithromycin | Azithromycin | 50 | 31 |
| Testosterone Cypionate | Testosterone Cypionate | 48 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | suppressed |
| Ezetimibe | Ezetimibe | 46 | suppressed |
| Metformin Hcl | Metformin Hcl | 46 | 14 |
| Anastrozole | Anastrozole | 45 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | suppressed |
| Gabapentin | Gabapentin | 42 | suppressed |
| Celecoxib | Celecoxib | 41 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | suppressed |
| Losartan Potassium | Losartan Potassium | 39 | 11 |
| Spironolactone | Spironolactone | 39 | 13 |
| Meloxicam | Meloxicam | 37 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 36 | suppressed |
| Cephalexin | Cephalexin | 35 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 34 | suppressed |
| Estradiol | Estradiol | 33 | suppressed |
| Potassium Chloride | Potassium Chloride | 33 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 14 |
| Valacyclovir | Valacyclovir Hcl | 31 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 30 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 29 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 27 | suppressed |
| Eliquis | Apixaban | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Prednisone | Prednisone | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 19 | suppressed |
| Furosemide | Furosemide | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Zaleplon | Zaleplon | 17 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Np Thyroid | Thyroid,pork | 14 | suppressed |
| Omeprazole | Omeprazole | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Simvastatin | Simvastatin | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $63,710.01 · 128 records | Lilly USA, LLC | AIRSUPRA, BREZTRI, CYCLOSET, Dojolvi, JARDIANCE, Jornay PM, Korlym, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, SPRAVATO, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error